dc.contributor.author | Stene, Guro Birgitte | |
dc.contributor.author | Balstad, Trude Rakel | |
dc.contributor.author | Leer, Anne Silja Mäkitalo | |
dc.contributor.author | Bye, Asta | |
dc.contributor.author | Kaasa, Stein | |
dc.contributor.author | Fallon, Marie T. | |
dc.contributor.author | Laird, Barry J | |
dc.contributor.author | Maddocks, Matthew | |
dc.contributor.author | Solheim, Tora Skeidsvoll | |
dc.date.accessioned | 2019-12-11T07:53:40Z | |
dc.date.available | 2019-12-11T07:53:40Z | |
dc.date.created | 2019-12-03T20:05:52Z | |
dc.date.issued | 2019 | |
dc.identifier.citation | Cancers. 2019, 11 (1925), . | nb_NO |
dc.identifier.issn | 2072-6694 | |
dc.identifier.uri | http://hdl.handle.net/11250/2632565 | |
dc.description.abstract | Background: Muscle mass and physical function (PF) are common co-primary endpoints in cancer cachexia trials, but there is a lack of data on how these outcomes interact over time. The aim of this secondary analysis of data from a trial investigating multimodal intervention for cancer cachexia (ClinicalTrials.gov: NCT01419145) is to explore whether changes in muscle mass and PF are associated with weight loss and cachexia status at baseline. Methods: Secondary analysis was conducted using data from a phase II randomized controlled trial including 46 patients with stage III–IV non-small cell lung cancer (n = 26) or inoperable pancreatic cancer (n = 20) due to commence chemotherapy. Cachexia status at baseline was classified according to international consensus. Muscle mass (assessed using computed tomography (CT)) and PF outcomes, i.e., Karnofsky performance status (KPS), self-reported PF (self-PF), handgrip strength (HGS), 6-minute walk test (6MWT), and physical activity (PA), were measured at baseline and after six weeks. Results: When compared according to cachexia status at baseline, patients with no/pre-cachexia had a mean loss of muscle mass (−5.3 cm2, p = 0.020) but no statistically significant change in PF outcomes. Patients with cachexia also lost muscle mass but to a lesser extent (−2.8 cm2, p = 0.146), but demonstrated a statistically significant decline in PF; KPS (−3.8 points, p = 0.030), self-PF (−8.8 points, p = 0.027), and HGS (−2.7 kg, p = 0.026). Conclusions: Weight loss history and cachexia status at baseline are of importance if one aims to detect changes in PF outcomes in cancer cachexia trials. To improve the use of co-primary endpoints that include PF in future trials, outcomes that have the potential to detect change relative to weight loss should be investigated further. | nb_NO |
dc.language.iso | eng | nb_NO |
dc.publisher | MDPI | nb_NO |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | Deterioration in Muscle Mass and Physical Function Differs According to Weight loss History in Cancer Cachexia | nb_NO |
dc.type | Journal article | nb_NO |
dc.type | Peer reviewed | nb_NO |
dc.description.version | publishedVersion | nb_NO |
dc.source.pagenumber | 14 | nb_NO |
dc.source.volume | 11 | nb_NO |
dc.source.journal | Cancers | nb_NO |
dc.source.issue | 1925 | nb_NO |
dc.identifier.doi | 10.3390/cancers11121925 | |
dc.identifier.cristin | 1756272 | |
dc.description.localcode | © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). | nb_NO |
cristin.unitcode | 194,65,30,0 | |
cristin.unitcode | 194,65,15,0 | |
cristin.unitname | Institutt for nevromedisin og bevegelsesvitenskap | |
cristin.unitname | Institutt for klinisk og molekylær medisin | |
cristin.ispublished | true | |
cristin.fulltext | postprint | |
cristin.qualitycode | 1 | |